CompletedPhase 2

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

United States10 participantsStarted 2018-06-13

Plain-language summary

This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients who underwent PTE or BPA for Chronic thromboembolic pulmonary hypertension (CTEPH) at least six months prior to screening and report ongoing subjective exercise limitation, * able to give consent * able to perform a exercise protocol Exclusion Criteria: * Patients with known Residual Pulmonary Hypertension (RPH) by RHC following PTE for CTEPH * ongoing PAH-specific vasodilator therapy * known contraindication to riociguat * a physical limitation to completing an exercise protocol

What they're measuring

Change in mean pulmonary arterial pressure

Timeframe: Baseline and 3 months

Change in cardiac output

Timeframe: Baseline and 3 months

Change in Pulmonary artery compliance

Timeframe: Baseline and 3 months

Trial details

NCT IDNCT03409588

SponsorUniversity of Colorado, Denver

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-01-26

View on ClinicalTrials.gov More Chronic Thromboembolic Disease (CTED) trials